SAN FRANCISCO, Jan. 7, 2020 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2020 at 2:30 p.m. Pacific Time.
The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. In addition, the company will webcast the Q&A breakout session immediately following its presentation at 3:00 p.m. Pacific Time. This Webcast will be available for replay until February 21, 2020.
About Nektar TherapeuticsNektar Therapeutics is a research-based, development-stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, autoimmune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Contacts:
For Investors:Vivian Wu of Nektar Therapeutics628-895-0661
For Media:Jodi Sievers of Nektar Therapeutics415-482-5593
Dan Budwick of [email protected]
Advertisement
The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. In addition, the company will webcast the Q&A breakout session immediately following its presentation at 3:00 p.m. Pacific Time. This Webcast will be available for replay until February 21, 2020.
Advertisement
About Nektar TherapeuticsNektar Therapeutics is a research-based, development-stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, autoimmune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Contacts:
For Investors:Vivian Wu of Nektar Therapeutics628-895-0661
For Media:Jodi Sievers of Nektar Therapeutics415-482-5593
Dan Budwick of [email protected]
View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-300982385.html
SOURCE Nektar Therapeutics
